Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123323 | 0.88 | HRH3 (0.37) | HRH3MCHR1 | |
| SCHEMBL24671068 | 0.85 | HRH3 (0.33) | HRH3MCHR1 | |
| SCHEMBL25482607 | 0.84 | PIK3CD (0.34) | — | |
| SCHEMBL14453916 | 0.80 | HRH3 (0.35) | HRH3 | |
| SCHEMBL25489002 | 0.79 | NOS3 (0.36) | HRH3 | |
| SCHEMBL25123178 | 0.79 | HRH3 (0.33) | HRH3MCHR1 | |
| SCHEMBL25122517 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL20046957 | 0.78 | HRH3 (0.33) | HRH3 | |
| SCHEMBL27425159 | 0.75 | HRH3 (0.38) | HRH3 | |
| SCHEMBL20046567 | 0.74 | HRH3 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023069514-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HRH3 3926/4885MCHR1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.